NCT06541093View on ClinicalTrials.gov

Study to Evaluate the Safety and Immunogenicity of an HIV-1 Vaccine Regimen of Adjuvanted UVAX-1107 Followed by Adjuvanted UVAX-1107 or Adjuvanted UVAX-1197 in Healthy Subjects Aged 25-55 Years.

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

January 30, 2024

Primary Completion Date

March 21, 2025

Study Completion Date

March 21, 2025

Conditions
AIDS/HIV - RelatedDisease Associated With AIDSVaccine-Preventable DiseasesHIV Infections
Interventions
BIOLOGICAL

UVAX-1107

Novel HIV-1 protein nanoparticles vaccine candidate (WT) mixed with Aluminum Hydroxide (AH) and CpG 1018 adjuvants

BIOLOGICAL

UVAX-1197

Novel HIV-1 protein nanoparticles vaccine candidate (GT) mixed with Aluminum Hydroxide (AH) and CpG 1018 adjuvants

OTHER

Placebo

Saline injection

Trial Locations (1)

3004

Nucleus Network Melbourne, Melbourne

All Listed Sponsors
lead

Uvax Bio LLC

INDUSTRY

NCT06541093 - Study to Evaluate the Safety and Immunogenicity of an HIV-1 Vaccine Regimen of Adjuvanted UVAX-1107 Followed by Adjuvanted UVAX-1107 or Adjuvanted UVAX-1197 in Healthy Subjects Aged 25-55 Years. | Biotech Hunter | Biotech Hunter